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In a recent article Catalán and colleagues [1] examined 
the expression of FcγRIIB in naïve, memory and plasma-
blast B cell subsets from peripheral blood of patients with 
rheumatoid arthritis (RA) and the results were correlated 
with levels of autoantibodies to cyclic citrullinated 
proteins (anti-CCP) detected in matching serum. Firstly, 
they observed reduced FcγRIIB expression in memory 
and plasmablast B cells from patients compared to the 
levels expressed on B cells from healthy controls. 
Secondly, the expression levels of FcγRIIB inversely 
correlated with the titre of anti-CCP antibodies in 
patients’ serum. Indeed, RA patients with low auto-
antibody titres expressed higher levels of this receptor. 
Th   irdly, they also report an increased frequency of CD86, 
usually up-regulated upon activation, on memory and 
naïve B cells [2]. Intriguingly, RA patients responding to 
adalimumab treatment display ‘normalized’ levels of 
CD86 only on memory B cells, but not on naïve B cells, 
and reduced expression of FcγRIIB only on naïve B cells, 
but not on memory B cells, and this was accompanied by 
unchanged levels of anti-CCP antibodies. Although these 
results are based on a relatively small group of patients, 
they could, if conﬁ   rmed, advocate the use of FcγRIIB 
expression coupled to anti-CCP responses as a predictive 
biomarker to monitor the early stage of disease and 
progression.
Human Fc receptors for IgG (FcγRI, FcγRIIA, FcγRIIC, 
FcγRIIIA, FcγRIIIB, FcγRIIB) exert diﬀ  erent  functions 
and have diverse aﬃ   nities for the Fc fragment of IgG, and 
these receptors are diﬀ  erentially expressed by a variety of 
cells [3]. B cells, however, exclusively express FcγRIIB, an 
inhibitory receptor that binds IgG immune complexes 
and negatively regulates B cell receptor activation. 
FcγRIIB is able to suppress or block B cell receptor 
activation by transmitting inhibitory signals via its 
cytoplasmic immunoreceptor tyrosine-based inhibitory 
(ITIM) motif upon simultaneous engagement with the 
B cell receptor [3]. Th  us, reduced levels of these regu-
latory proteins could result in a lower threshold for B cell 
activation and stronger activating signals following B cell 
receptor cross-linking.
Strong evidence supports the hypothesis that FcγRIIB 
and IgG immune complexes may play a central role in the 
regulation of humoral responses, and that the defects in 
this system could contribute to the development of 
autoimmunity. Th   ere is evidence that FcγRIIB preferen-
tially limits activation of high aﬃ   nity autoreactive B cells 
in the periphery [4]. Indeed, mice lacking the FcγRIIB 
receptor develop exacerbated autoimmunity compared to 
wild-type mice [5]. Furthermore, when the pathogenicity 
of human RA-associated autoantibodies was tested by 
passive transfer into mice deﬁ   cient for FcγRIIB, mice 
developed inﬂ  ammation and histological lesions consis-
tent with arthritis, supporting a direct role for humoral 
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Aberrant immune responses play a pivotal role in the 
processes that cause infl  ammation and joint damage 
in patients with rheumatoid arthritis (RA). Polyclonal 
B cell activation and the production of autoantibodies 
are immunological hallmarks of the disease. 
However, controversy surrounds the pathogenicity of 
autoantibodies, mainly because not all patients are 
seropositive (10% of RA patients are seronegative), 
suggesting that they could be markers rather than 
makers of disease. Catalán and collaborators report that 
patients with RA display reduced expression of FcγRIIB 
on memory B cells and plasma cells, which inversely 
correlates with autoantibody levels. Considering 
that FcγRIIB stimulation down-regulates antibody 
production, this work strengthens the link between 
autoantibodies and pathogenicity.
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Th   e link between the inhibitory FcγRIIB and the modu-
la  tion of B cell activity and humoral tolerance has also 
been translated into humans. Expression of FcγRIIB was 
found to be considerably decreased in memory B cells 
from patients with systemic lupus erythematosus 
compared to the levels detected in healthy controls. Th  is 
directly correlated with decreased FcγRIIB-mediated 
suppression of B cell receptor-induced down-stream 
signal  ling events [7]. Furthermore, several studies link 
FcγRIIB polymorphisms to increased susceptibility to 
systemic lupus erythematosus [8] and with joint damage 
in patients with RA [9]. However, although it seems a 
likely candidate, a direct role for inhibitory FcγRIIB in 
the pathogenesis of RA has not been demonstrated.
FcγRIIB is diﬀ  erentially expressed on healthy B cells, 
depending on the stage of B cell development and, since 
FcγRIIB helps to regulate B cell receptor-mediated 
stimulatory signals, it acts as a gatekeeper controlling 
B  cell proliferation and maturation [10]. However, the 
results presented by Catalán and colleagues did not show 
any stringent relationship between B cell activation 
measured by CD86 expression and levels of FcγRIIB, 
indicating that the relationship between FcγRIIB expres-
sion and B cell activation, especially in the context of 
inﬂ  ammatory disease, requires further exploration. Th  e 
results presented by Catalán and colleagues go some way 
to support the hypothesis that RA is associated with 
decreased negative feedback of humoral and eﬀ  ector 
immune responses. In addition, although not formally 
proven, it is tempting to speculate that the increased 
levels of CD86 expression on naïve B cells may be 
involved in and precede the down-regulation of FcγRIIB 
on memory B cells. Less clear is why in a less inﬂ  amed 
environment (that is, after anti-TNFα treatment) the 
expression of FcγRIIB is not recovered to similar levels to 
those detected in healthy individuals.
Defects in other inhibitory receptors have also been 
linked with RA pathogenesis, including reduced expres-
sion of CTLA-4 (cytotoxic T-lymphocyte antigen 4) in 
regulatory T cells from patients [11]. In the case of 
CTLA-4, reduced expression was also asso  ciated with 
abnormal function, but it remains to be seen whether 
FcγRIIB-mediated signalling is fully functional in B cells 
from RA patients. Abnormal FcγRIIB function could go 
some way to explain the discrepancy between FcγRIIB 
expression and B cell activation as determined by CD86 
expression.
Finally, if FcγRIIB truly acts as a late checkpoint at the 
level of class-switched B cells or antibody-producing 
plasmablasts/plasma cells, and considering that auto-
reactive B cells are generated during the process of 
aﬃ     nity maturation, then the relationship between 
FcγRIIB expression in autoantibody-mediated disease 
such as RA merits further exploration. Indeed, diﬀ   er en tial 
FcγRIIB expression may inﬂ  uence other B cell functions, 
including antigen presentation and cytokine production, 
involved in RA pathogenesis.
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